Harrow Health
Yahoo Finance • 10 days ago
Harrow Announces Agenda and Speakers for Investor & Analyst Day
NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, Sep... Full story
- MS
Mentioned:
Yahoo Finance • 10 days ago
Implied FYX Analyst Target Price: $122
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
Yahoo Finance • 16 days ago
Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030
NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $250.0 mi... Full story
Yahoo Finance • 17 days ago
Harrow launches $250M debt offering
* Harrow (NASDAQ:HROW [https://seekingalpha.com/symbol/HROW]) has commenced a private offering of $250.0 million aggregate principal amount of senior unsecured notes due 2030. * The company plans to use proceeds from the offering to fu... Full story
Yahoo Finance • 17 days ago
Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider... Full story
Yahoo Finance • 27 days ago
HARROW INC (NASDAQ:HROW) Presents High Growth Momentum and Technical Breakout Opportunity
Harrow Inc (NASDAQ:HROW [https://www.chartmill.com/stock/quote/HROW]) appears as an interesting candidate for investors using a high growth momentum strategy paired with technical breakout analysis. This method centers on finding companies... Full story
Yahoo Finance • last month
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@poml... Full story
- AAPL
Mentioned:
Yahoo Finance • last month
Harrow Announces Second-Quarter 2025 Financial Results
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalen... Full story
Yahoo Finance • 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@poml... Full story
Yahoo Finance • 2 months ago
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference... Full story
Yahoo Finance • 2 months ago
H.C. Wainwright reiterates Buy rating on Harrow Health stock at $60 target
Investing.com - H.C. Wainwright has reiterated its Buy rating and $60.00 price target on Harrow Health (NASDAQ:HROW), currently trading at $36.14, following the company’s announcement of a definitive agreement with Samsung (KS:005930) Bioe... Full story
Yahoo Finance • 2 months ago
Harrow jumps as Cantor initiates with Bullish view on conservative outlook
[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Harrow (NASDAQ:HROW [https://seekingalpha.com/symbol/HROW]) shares added ~11% in the morning hours on Friday after Cantor Fitzgerald launched the Nashville, Tennessee-ba... Full story
Yahoo Finance • 2 months ago
Cantor Fitzgerald initiates Harrow Health stock with Overweight rating
Investing.com - Cantor Fitzgerald initiated coverage on Harrow Health (NASDAQ:HROW) with an Overweight rating and a $76.00 price target on Friday. According to InvestingPro data, this target represents significant upside from the current s... Full story
Yahoo Finance • 4 months ago
Harrow wins new Outperform at William Blair after licensing deal for pain drug
[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images William Blair on Tuesday initiated its coverage on Harrow (NASDAQ:HROW [https://seekingalpha.com/symbol/HROW]) with an Outperform recommendation after the Nashville, Ten... Full story
Yahoo Finance • 4 months ago
Harrow acquires U.S. commercial rights to BYQLOVI from Formosa Pharmaceuticals
Harrow (NASDAQ:HROW [https://seekingalpha.com/symbol/HROW]) and Taiwan-based Formosa Pharmaceuticals Monday announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI (clobetasol propionat... Full story
Yahoo Finance • 2 years ago
Investigation Into Harrow, Inc. (HROW) Announced by Holzer & Holzer, LLC
ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) complied with federal securities laws. On November 13, 2023, Harrow released its third quart... Full story
Yahoo Finance • 2 years ago
Why Shares of Harrow Health Are Slumping Friday
Shares of Harrow Health (NASDAQ: HROW) were down more than 24% as of 1:45 p.m. ET Friday after the company reported first-quarter earnings following the close of trading Thursday. It set a quarterly record for revenue -- $26.1 million, up... Full story
Yahoo Finance • 3 years ago
Harrow Health, Inc.: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 27, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) investo... Full story
Yahoo Finance • 3 years ago
Harrow Health Shareholder News: Johnson Fistel Encourages Harrow Health Shareholders with Losses to Contact the Firm Regarding Class Action Investigation
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Harrow Health, Inc. ("Harrow Health" or the "Company") (NASDAQ: HROW), any of its executive officers, or others violate... Full story
